Taysha Gene Therapies, Inc. (TSHA) — Stock Score Summary

Taysha Gene Therapies, Inc. (TSHA) has a MoatMap StockRank of 26/100 based on Quality (25/100), Value (33/100), and Momentum (55/100) factor scores. The current signal is SELL. Taysha Gene Therapies is a clinical-stage gene therapy developer. It is highly speculative, pre-revenue, and faces significant clinical and regulatory hurdles, which does not fit our quality compounder mandate.

Taysha Gene Therapies, Inc. is a clinical-stage gene therapy company focused on developing therapies for monogenic central nervous system (CNS) diseases. The company utilizes a robust adeno-associated virus (AAV) gene therapy platform to address a range of neurological disorders with high unmet medical needs. Taysha operates as a specialized player in the burgeoning gene therapy sector, aiming to deliver potentially curative treatments for severe inherited brain disorders.

Key Financial Metrics

Price$5.36
Market Cap$1.7B
P/E (Forward)-13.31
Price/Book6.80
Return on Equity-97.3%
Return on Invested Capital-34.4%
Debt/Equity32.34
Gross Margin100.0%
Operating Margin-1774.4%
Free Cash Flow$-73M

Taysha Gene Therapies, Inc. operates in the Biotechnology industry, part of the Healthcare sector (United States).

Frequently Asked Questions

What is Taysha Gene Therapies, Inc.’s (TSHA) StockRank?
MoatMap’s StockRank for Taysha Gene Therapies, Inc. (TSHA) is 26/100, with a Sell signal. It is a composite of Quality (25), Value (33), and Momentum (55) factor ranks across MoatMap’s 19,000+ stock universe.
Does Taysha Gene Therapies, Inc. have an economic moat?
Taysha Gene Therapies, Inc. (TSHA) has a Quality factor score of 25/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the characteristics of a moated business.
Is Taysha Gene Therapies, Inc. a buy, hold, or sell?
MoatMap’s current signal for Taysha Gene Therapies, Inc. (TSHA) is Sell, based on a StockRank of 26/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.
What sector is Taysha Gene Therapies, Inc. in?
Taysha Gene Therapies, Inc. (TSHA) operates in the Healthcare sector, specifically the Biotechnology industry (United States).
Browse all ranked stocksTSHA deep dive reportAI ChampionsHow we score stocksSense-check another stock